Antibody Inhibition of CD23 Liposome Binding
| MoAb Added . | Inhibition of CD23-Liposome Binding . |
|---|---|
| None | − |
| CD23* | + |
| CD5† | − |
| CD11a | − |
| CD11b | − |
| CD11c | − |
| CD18 | − |
| CD19† | − |
| CD21‡ | − |
| CD22 | − |
| CD54† | − |
| MoAb Added . | Inhibition of CD23-Liposome Binding . |
|---|---|
| None | − |
| CD23* | + |
| CD5† | − |
| CD11a | − |
| CD11b | − |
| CD11c | − |
| CD18 | − |
| CD19† | − |
| CD21‡ | − |
| CD22 | − |
| CD54† | − |
SMS-SB cells were harvested, washed, and preincubated with antibodies of the specificities noted in the Table for 1 hour at 4°C. After further washing to remove unbound antibody, CD23-containing liposomes were added and binding assessed by flow cytometry. Binding was scored in relation to the data presented in Fig 7; eg, − represents maximal binding of liposomes to SMS-SB cells (no inhibition) and + is equivalent to the inhibition noted in Fig 7 with EBVCS4.
Liposomes were preincubated with anti-CD23 antibody rather than SMS-SB cells; EBVCS4 and MoAb 254 were used, and Rb55 also partially inhibited liposome binding.
The antigen is detectable by direct FITC-MoAb staining of SMS-SB cells.
The following anti-CD21 MoAbs were tested: BU33 (The Binding Site, Birmingham, UK), THB5 (GBRI), MCA644 (Serotec), CR2 (Becton Dickinson), and IOB1a (Immunotech, Marseille, France).